Ari Maizel Biography and Net Worth

Chief Commercial Officer of Axsome Therapeutics

Mr. Maizel has served as our Chief Commercial Officer since October 2024 and has been a member of the Axsome team since October 2023.

Prior to joining Axsome, Mr. Maizel was the Vice President, US Psychiatry at AbbVie where he oversaw sales and marketing for a multi-billion-dollar franchise. Mr. Maizel held positions of increasing responsibility in sales and marketing throughout his career at AbbVie (formerly Allergan), Dendreon Corporation, and Johnson & Johnson across a range of therapeutic areas including CNS, immunology, oncology, gastroenterology, and women’s health. Mr. Maizel began his career at ArrowPath Venture Partners, an early-stage technology investment fund, and was a strategy consultant with Sg2, supporting hospitals and health systems around the world. He earned his BA in Finance from the George Washington University, and MBA in Health Sector Management and Marketing from the Fuqua School of Business at Duke University.

How do I contact Ari Maizel?: The corporate mailing address for Mr. Maizel and other Axsome Therapeutics executives is 200 BROADWAY 3RD FLOOR, NEW YORK NY, 10038. Axsome Therapeutics can also be reached via phone at (212) 332-3241. Learn More on Ari Maizel's contact information.
Has Ari Maizel been buying or selling shares of Axsome Therapeutics?: Within the last three months, Ari Maizel has sold $1,383,300.00 of Axsome Therapeutics stock. Most recently, Ari Maizel sold 7,500 shares of the business's stock in a transaction on Wednesday, January 21st. The shares were sold at an average price of $184.44, for a transaction totalling $1,383,300.00. Learn More on Ari Maizel's trading history.
Who are Axsome Therapeutics' active insiders?: Axsome Therapeutics' insider roster includes Mark Coleman (Director), Mark Jacobson (COO), Roger Jeffs (Director), Ari Maizel (Chief Commercial Officer), Hunter Murdock (General Counsel), Nick Pizzie (CFO), Mark Saad (Director), and Herriot Tabuteau (CEO). Learn More on Axsome Therapeutics' active insiders.
Are insiders buying or selling shares of Axsome Therapeutics?: During the last twelve months, Axsome Therapeutics insiders bought shares 1 times. They purchased a total of 1,575 shares worth more than $200,466.00. During the last twelve months, insiders at the sold shares 34 times. They sold a total of 780,172 shares worth more than $106,243,349.08. The most recent insider tranaction occured on January, 22nd when CFO Nick Pizzie sold 12,000 shares worth more than $2,255,040.00. Insiders at Axsome Therapeutics own 22.3% of the company. Learn More about insider trades at Axsome Therapeutics.
Information on this page was last updated on 1/22/2026.

Ari Maizel Insider Trading History at Axsome Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/21/2026	Sell	7,500	$184.44	$1,383,300.00

Ari Maizel Buying and Selling Activity at Axsome Therapeutics

Axsome Therapeutics Company Overview

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Today's Range

Now: $184.25

$180.56

$188.00

50 Day Range

MA: $163.29

$142.09

$189.10

2 Week Range

Now: $184.25

$86.99

$191.50

Volume

745,724 shs

Average Volume

730,031 shs

Market Capitalization

$9.29 billion

P/E Ratio

N/A

Dividend Yield